0B68 Cristofanilli, Massimo - Thomas Jefferson University - Thomas Jefferson University

Massimo Cristofanilli, MD

Contact Dr. Cristofanilli

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy
  2. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer
  3. Gene expression profiles of inflammatory breast cancer: Correlation with response to neoadjuvant chemotherapy and metastasis-free survival
  4. Circulating tumour cells: Telling the truth about metastasis
  5. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib
  6. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations
  7. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition
  8. Presence of anaplastic lymphoma kinase in inflammatory breast cancer
  9. The Third International Inflammatory Breast Cancer Conference
  10. Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): A multicenter, double-blind, prospective trial
  11. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells
  12. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma
  13. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients
  14. Uncovering the molecular secrets of inflammatory breast cancer biology: An integrated analysis of three distinct affymetrix gene expression datasets
  15. Circulating tumor cells in metastatic colorectal cancer: Do we need an alternative cutoff?
  16. Circulating tumor DNA to monitor metastatic breast cancer [5]
  17. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer
  18. Inflammatory breast cancer (IBC): Clues for targeted therapies
  19. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy
  20. Genomic and expression analysis of microdissected inflammatory breast cancer